Timing, incidence and management of delayed bleeding after partial nephrectomy in patients at risk for recurrent, bilateral, multifocal renal tumors.

Autor: Gomella PT; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Solomon J; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Ahdoot M; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Gurram S; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Lebastchi AH; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Levy E; Interventional Radiology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD., Krishnasamy V; University of Alabama Birmingham, Birmingham, AL., Kassin MT; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD; Interventional Radiology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD., Chang R; Interventional Radiology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD., Wood BJ; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD; Interventional Radiology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD., Linehan WM; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Ball MW; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: mark.ball@nih.gov.

Publikováno v: Urologic oncology [Urol Oncol] 2024 Jul; Vol. 42 (7), pp. 222.e1-222.e7. Date of Electronic Publication: 2024 Apr 12.

Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.

Autor: Ahdoot M; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: michael.ahdoot@cshs.org., Lebastchi AH; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Long L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda, MD, USA., Wilbur AR; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gomella PT; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mehralivand S; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Molecular Imaging Program, Center for Cancer Research, National Institute of Health, Bethesda, MD, USA., Daneshvar MA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yerram NK; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., O'Connor LP; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Wang AZ; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gurram S; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Bloom J; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Siddiqui MM; Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA., Linehan WM; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Merino M; Translational Surgical Pathology Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Choyke PL; Molecular Imaging Program, Center for Cancer Research, National Institute of Health, Bethesda, MD, USA., Pinsky P; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Parnes H; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Shih JH; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda, MD, USA., Turkbey B; Molecular Imaging Program, Center for Cancer Research, National Institute of Health, Bethesda, MD, USA., Wood BJ; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Interventional Radiology, Radiology and Imaging Sciences, National Institutes of Health Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Pinto PA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Publikováno v: European urology oncology [Eur Urol Oncol] 2022 Apr; Vol. 5 (2), pp. 176-186. Date of Electronic Publication: 2021 Apr 10.

Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?

Autor: Williams C; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Ahdoot M; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Daneshvar MA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Hague C; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Wilbur AR; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Gomella PT; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Shih J; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Khondakar N; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Yerram N; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Mehralivand S; Molecular Imaging Program, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland., Gurram S; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Siddiqui M; Director of Urologic Oncology and Robotic Surgery, VA Medical Center, University of Maryland, Baltimore, Maryland., Pinsky P; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Parnes H; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Merino M; Translational Surgical Pathology Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Wood B; Center for Interventional Oncology, National Cancer Institute, & Interventional Radiology, Radiology and Imaging Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Turkbey B; Molecular Imaging Program, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland., Pinto PA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Publikováno v: The Journal of urology [J Urol] 2022 Jan; Vol. 207 (1), pp. 95-107. Date of Electronic Publication: 2021 Aug 26.

Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management.

Autor: Gomella PT; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Linehan WM; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Ball MW; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Publikováno v: Genes [Genes (Basel)] 2021 Feb 11; Vol. 12 (2). Date of Electronic Publication: 2021 Feb 11.

PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.

Autor: Wang AZ; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., O’Conno LP; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Yerram NK; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Long L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Zeng J; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Mehralivand S; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Harmon SA; Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Maryland., Lebastchi AH; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Ahdoot M; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Gomella PT; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Gurram S; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Choyke PL; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Merino MJ; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Shih JH; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Wood BJ; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Turkbey B; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Pinto PA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Publikováno v: The Journal of urology [J Urol] 2020 Dec; Vol. 204 (6), pp. 1229-1235. Date of Electronic Publication: 2020 Jul 27.